Free Trial
NASDAQ:NLSP

NLS Pharmaceutics (NLSP) Stock Price, News & Analysis

NLS Pharmaceutics logo
$3.98 -0.17 (-4.10%)
(As of 10:27 AM ET)

About NLS Pharmaceutics Stock (NASDAQ:NLSP)

Key Stats

Today's Range
$3.87
$4.03
50-Day Range
$0.12
$5.34
52-Week Range
$3.51
$29.08
Volume
4,254 shs
Average Volume
152,713 shs
Market Capitalization
$15.18 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

NLS Pharmaceutics AG, a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies for patients with rare and complex central nervous system disorders. The company is focusing on the development of treatments for narcolepsy, idiopathic hypersomnia, and other rare sleep disorders, as well as neurodevelopmental disorders, such as attention deficit hyperactivity disorder (ADHD). Its lead product candidates include Quilience to treat excessive daytime sleepiness and cataplexy; and Nolazol for the treatment of ADHD. The company also developing NLS-4, a selective dopamine reuptake inhibitor to prevent rare sleep disorders; NLS-3, a repurposed reverse ester of methylphenidate for treatment of ADHD; NLS-8, a melatonin ML1A receptor agonist, improved scopolamine-induced amnesia; NLS-11, a norepinephrine and dopamine reuptake inhibitor and muscarinic M1, M2, M3 receptor antagonist; and NLS-12, a norepinephrine and dopamine reuptake inhibitor and muscarinic M4 receptor antagonist. NLS Pharmaceutics AG was incorporated in 2015 and is based in Zurich, Switzerland.

NLS Pharmaceutics Stock Analysis - MarketRank™

See Top Rated MarketRank™ Stocks
14th Percentile Overall Score

NLSP MarketRank™: 

NLS Pharmaceutics scored higher than 14% of companies evaluated by MarketBeat, and ranked 912th out of 967 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    There is not enough analysis data for NLS Pharmaceutics.

  • Price to Book Value per Share Ratio

    NLS Pharmaceutics has a P/B Ratio of 0.37. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

  • Percentage of Shares Shorted

    2.88% of the float of NLS Pharmaceutics has been sold short.
  • Short Interest Ratio / Days to Cover

    NLS Pharmaceutics has a short interest ratio ("days to cover") of 0.7, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in NLS Pharmaceutics has recently increased by 29.18%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    NLS Pharmaceutics does not currently pay a dividend.

  • Dividend Growth

    NLS Pharmaceutics does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    2.88% of the float of NLS Pharmaceutics has been sold short.
  • Short Interest Ratio / Days to Cover

    NLS Pharmaceutics has a short interest ratio ("days to cover") of 0.7, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in NLS Pharmaceutics has recently increased by 29.18%, indicating that investor sentiment is decreasing significantly.
  • News Sentiment

    NLS Pharmaceutics has a news sentiment score of 0.29. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 8 news articles for NLS Pharmaceutics this week, compared to 0 articles on an average week.
  • Search Interest

    2 people have searched for NLSP on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, NLS Pharmaceutics insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    16.40% of the stock of NLS Pharmaceutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Read more about NLS Pharmaceutics' insider trading history.
Receive NLSP Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for NLS Pharmaceutics and its competitors with MarketBeat's FREE daily newsletter.

NLSP Stock News Headlines

NLS Pharmaceutics Announces Strategic Capital Restructuring
NLS Pharmaceutics and Kadimastem Announce Strategic Merger
625,000% Gain
Imagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetched, but results like this are within reach with the right knowledge and timing in the altcoin market. Plus, you’ll get $10 in real Bitcoin when you stay to the end of the call and take a short quiz.
NLS Pharmaceutics, Kadimastem enter definitive merger agreement
NLS Pharmaceutics Merges with Kadimastem for Strategic Growth
See More Headlines

NLSP Stock Analysis - Frequently Asked Questions

NLS Pharmaceutics' stock was trading at $0.5899 at the start of the year. Since then, NLSP shares have increased by 603.5% and is now trading at $4.15.
View the best growth stocks for 2024 here
.

NLS Pharmaceutics (NLSP) raised $20 million in an initial public offering on Friday, January 29th 2021. The company issued 3,600,000 shares at $5.00-$6.00 per share. Maxim Group LLC acted as the underwriter for the IPO and Brookline Capital (A division of Arcadia Securities) was co-manager.

Shares of NLSP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Based on aggregate information from My MarketBeat watchlists, some other companies that NLS Pharmaceutics investors own include Intel (INTC), Meta Platforms (META), Immunic (IMUX), Seres Therapeutics (MCRB), NVIDIA (NVDA), Palantir Technologies (PLTR) and Tesla (TSLA).

Company Calendar

Today
11/08/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:NLSP
Employees
6
Year Founded
N/A

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$11.14 per share

Miscellaneous

Free Float
3,189,000
Market Cap
$15.83 million
Optionable
Not Optionable
Beta
-0.51
10 Best Cheap Stocks to Buy Now Cover

MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.

Get This Free Report

This page (NASDAQ:NLSP) was last updated on 11/8/2024 by MarketBeat.com Staff
From Our Partners